ANIP up +3.37% percent Today $ANIP High is at 56.74 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 10:58 AM

ANIP up +3.37% percent Today $ANIP High is at 56.74 and the Low 54.01 with current volume of 81,477.

Recent News posted below.

ANI Pharmaceuticals Inc ANIP other info.
http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/

ANIP ANI Pharmaceuticals Inc Recent Headline News

Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 12 mins ago
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 56.01 (+2.06), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26), PBYI: 223.58 (+7.36)

Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 306.96 (+1.53), ANIP: 56.01 (+2.06), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26)

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 56.01 (+2.06), ICPT: 159.47 (-3.11), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26)

Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 56.01 (+2.06)

ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 56.01 (+2.06), SCMP: 11.94 (+0.64)

Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 56.01 (+2.06)

Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 306.96 (+1.53), ANIP: 56.01 (+2.06), CLDX: 17.90 (+3.74), AMAG: 34.69 (+0.69)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.57 (+0.11), ANIP: 56.01 (+2.06), ACGL: 56.85 (-0.45), ACCO: 8.96 (-0.03), FLWS: 8.84 (-0.15)

ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 56.01 (+2.06)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.37 (-0.61), HBNK: 19.95 (+0.17), ASMI: 41.46 (+0.20), RRGB: 68.69 (+0.18), SAPE: 24.68 (unch), PLUG: 3.72 (unch), ANIP: 56.01 (+2.06), ODP: 6.57 (-0.22), MTEX: 21.98 (+1.67), JAXB: 11.75 (-0.15), ALQA: 5.10 (+0.05), YRCW: 23.46 (-0.27)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 6.13 (+0.05), NEO: 4.69 (+0.01), AU: 9.39 (-0.17), FNHC: 24.57 (-0.16), AMS: 2.53 (-0.19), NYMX: 0.57 (+0.02), AMDA: 1.37 (+0.15), CVD: 100.35 (+0.05), GBIM: 6.50 (+0.20), RCAP: 11.84 (-0.25), KBIO: 1.96 (-0.14), COOL: 0.81 (-0.09), SAPE: 24.68 (unch), XTLB: 2.58 (+0.13), GERN: 3.03 (+0.27), ANIP: 56.01 (+2.06), BBLU: 1.32 (+0.02), NXTD: 2.31 (unch), AP: 18.78 (-0.10), ALQA: 5.10 (+0.05)

ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST

ANIP: 56.01 (+2.06)

ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 56.01 (+2.06)

ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST

ANIP: 56.01 (+2.06)

ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 56.01 (+2.06)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.84 (+0.03), SYY: 38.86 (+0.28), L: 42.55 (-0.23), EEP: 37.93 (+0.59), SNH: 22.21 (+0.03), INN: 11.47 (-0.07), ITG: 19.61 (+0.10), NSP: 32.90 (-0.08), S: 5.01 (-0.04), ALE: 49.97 (+0.14), GVA: 35.92 (-0.35), MCY: 53.86 (-0.19), ARNA: 4.58 (+0.05), CHD: 73.72 (+0.19), ARE: 82.56 (+0.24), USAK: 18.56 (+0.11), BWP: 16.76 (-0.19), KRG: 26.18 (-0.02), CYOU: 22.74 (-1.13), MNKD: 6.22 (+0.06), HNT: 50.87 (+1.07), AMH: 17.24 (-0.03), ARCB: 42.42 (-0.19), ANIP: 56.01 (+2.06), AMG: 195.41 (-1.53), HAE: 36.98 (-0.15), SOHU: 49.42 (-1.54), CNA: 38.94 (-0.18)

ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 107.66 (+0.76), MACK: 8.70 (+0.22), ANIP: 56.01 (+2.06), ILMN: 182.54 (+2.04)

ANI Pharma reports November 3
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:35AM CDT

ANIP: 56.01 (+2.06)

5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 56.01 (+2.06), KTOS: 5.32 (-0.08), BLOX: 17.04 (+0.18), CSLT: 11.17 (-0.69), FPRX: 15.44 (+0.25)

ANI Pharmaceuticals Inc. (ANIP) Stock Research Links

ANIP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...